Topics

Neural Influence on NSCLC Immunotherapy Efficacy

Tumor Microenvironment Cancer Immunotherapy Intercellular Communication & Diseases Chronic Inflammation

Neural influence on non-small cell lung cancer immunotherapy refers to the capacity of autonomic and sensory signaling to alter the tumor, stromal, vascular, and immune conditions that determine response to immune checkpoint inhibition. PD-1 and PD-L1 blockade can restore antitumor T-cell activity, but efficacy varies widely even among tumors with similar conventional biomarkers. Cancer neuro-immunology adds nerve density, neurotransmitter exposure, stress physiology, and neural-receptor expression as potential sources of that variation. Peripheral nerve fibers can release catecholamines or neuropeptides, while tumor and immune cells express corresponding receptors. The field is highly active but remains less mature than genomic or PD-L1-based stratification, and direct NSCLC evidence is still limited[1].

Adrenergic signaling provides the clearest mechanistic model. In mouse tumors, norepinephrine-driven beta-adrenergic signaling in host immune cells reduced effector CD8 T-cell features, increased an immunologically restrained tumor state, and weakened anti-PD-1 efficacy; physiological, genetic, and pharmacological reduction of the pathway improved checkpoint response. Separate mouse vaccination experiments showed that beta-receptor activation primarily suppressed initial CD8 T-cell priming in tumor-draining lymph nodes, whereas propranolol increased tumor-infiltrating CD8 cells and vaccine efficacy. These studies identify a plausible route from sympathetic activity to altered T-cell metabolism, priming, trafficking, and exhaustion. They do not prove that the same pathway controls checkpoint response in every human lung tumor or that nonspecific beta blockade acts only through immunity[1][2][3].

The most direct lung-cancer evidence is observational. A 2025 multicenter retrospective study evaluated 462 patients with advanced lung cancer receiving immune checkpoint inhibitors; after propensity-score matching, beta-blocker use was associated with longer progression-free survival and higher objective response, including in the NSCLC subgroup. Overall survival did not improve significantly. Cardiovascular indication, comorbidity, beta-blocker selectivity, dose, adherence, and other treatments can confound such comparisons, even after statistical adjustment. The study therefore supports prospective testing and biomarker development rather than routine beta-blocker addition solely to enhance immunotherapy. Neural-state assessment could combine tumor innervation, adrenergic-receptor expression, circulating stress mediators, heart-rate variability, medication exposure, and spatial immune profiling[1][4].

Key gaps are causality, neural specificity, and clinical selection. Trials should distinguish direct effects on cancer cells, vessels, myeloid cells, and lymphocytes, and should stratify by beta-blocker type and cardiovascular status. Serial biopsies or blood should establish whether pathway inhibition changes T-cell priming, infiltration, exhaustion, or only tumor perfusion. A prospective study could randomize an adrenergic intervention only among eligible patients, use uniform checkpoint regimens, and predefine progression-free survival, overall survival, immune pharmacodynamics, cardiovascular safety, and patient-reported stress. Stress, pain, smoking-related lung disease, corticosteroids, brain metastases, and autonomic comorbidity may independently influence both drug exposure and outcomes. Investigators must also separate tumor-local neural signaling from systemic catecholamine exposure and account for receptor expression on different cell types. That distinction is essential for both efficacy and safety. Future studies should test a prespecified neural biomarker alongside standard variables such as driver mutations, PD-L1, tumor burden, and treatment regimen. Until randomized evidence exists, neural modulation is best treated as a mechanistic hypothesis and trial strategy, not a validated determinant of NSCLC checkpoint efficacy[1][2][3][4].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
PINK1/Parkin   Oxidative Phosphorylation   STING   IFNAR   Mitochondrial Metabolism   Bacterial   Apoptosis  
Cancer   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Parkinson's Disease   Rheumatoid Arthritis  
189
HY-101461 Methyl-β-cyclodextrin
Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin) is a cyclic heptasaccharide used to deliver hydrophobic agents based on its property of solubilizing non-polar substances. Methyl-β-cyclodextrin is also extensively used as a cholesterol-depleting reagent. Methyl-β-cyclodextrin strongly reduces clathrin-dependent endocytosis. Methyl-β-cyclodextrin blocks cell migrasome formation.
Environmental Pollutants   Biochemical Assay Reagents  
Cancer  
114
HY-B0468 Isoprenaline hydrochloride
Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma.
Adrenergic Receptor   Endogenous Metabolite  
Depression   SARS-CoV-2 Infection   Hypertension   Obesity  
94
HY-L006 GPCR/G Protein Compound Library
GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery. MCE provides a unique collection of 3,479 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Signaling Pathway Targeting Libraries

93
HY-L007 Immunology/Inflammation Compound Library
The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. MCE designs a unique collection of 8,534 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Signaling Pathway Targeting Libraries

89
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L109 Protein-protein Interaction Inhibitor Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 813 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Signaling Pathway Targeting Libraries

86
HY-L013 Neuronal Signaling Compound Library
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders. MCE designs a unique collection of 3,934 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Signaling Pathway Targeting Libraries

84
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,012 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,113 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L047 Endocrinology Compound Library
The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function. The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease. MCE offers a unique collection of 902 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Disease Focused Libraries

83
HY-L072 Exosomes Compound Library
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture. Exosomes contain nucleic acids, proteins, lipids, amino acids, and metabolites, etc. Their diverse constituents can reflect their cell of origin. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Proteins, metabolites, and nucleic acids delivered by exosomes into recipient cells effectively alter their biological response. Such exosome-mediated responses can be disease promoting or restraining. The biology of exosomes in disease is still emerging, and the number of studies addressing their utility in the diagnosis and treatment of various pathologies has increased substantially. MCE supplies a unique collection of 56 compounds with the activity of inhibiting or stimulating exsomes secretion/biosynthesis. MCE Exosomes Compound Library is a useful tool for exsomes research.

Signaling Pathway Targeting Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,276 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L145 Antihypertensive Compound Library
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 925 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Disease Focused Libraries

83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,021 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Disease Focused Libraries

83
HY-L171 Anti-Hematopathy Compound Library
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,329 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Disease Focused Libraries

83
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 149 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Compound Characteristic Classified Libraries

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,181 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 268 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 57 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Metabolism Focused Libraries

83
HY-L260 KRAS Targeted Compound Library
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2. MCE KRAS Targeted Compound Library contains 79 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
STING   IFNAR   Influenza Virus  
Lung Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection  
77
HY-13715A Norepinephrine hydrochloride
Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors.
Adrenergic Receptor   Autophagy   Endogenous Metabolite  
Cancer   Depression   Cardiovascular Disease   Glucose Metabolism   Obesity  
74
HY-16141 Cilengitide
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
Integrin   Autophagy   Apoptosis   STAT   PD-1/PD-L1  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
74
HY-13715 Norepinephrine
Norepinephrine (Levarterenol; L-Noradrenaline) is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors.
Endogenous Metabolite   Adrenergic Receptor   Autophagy  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
74
HY-100017 BAY-876
BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis.
GLUT   Disulfidptosis  
Digestive System Disease   Ovarian Cancer   Digestive System Inflammation  
59
HY-B0573 Propranolol hydrochloride
Propranolol hydrochloride is a nonselective and BBB-permeableβ-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor   Bacterial  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   SARS-CoV-2 Infection   Alzheimer's Disease   Hypertension  
50
HY-B0573B Propranolol
Propranolol is a nonselective and BBB-permeable β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
Adrenergic Receptor   Bacterial  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Alzheimer's Disease   Psoriasis   Hypertension  
50
HY-13951 Zenidolol hydrochloride
Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with Kis of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.
Adrenergic Receptor  
Metabolic or Endocrine Disease   Depression   Alzheimer's Disease   Hypertension  
47
HY-A0070A Liothyronine
Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR.
Thyroid Hormone Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease  
44
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
42
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
42
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
40
HY-P9902A Pembrolizumab (anti-PD-1)
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

Species: Human

PD-1/PD-L1  
Triple-Negative Breast Cancer  
35
HY-B0769 Phenylephrine
(R)-(-)-Phenylephrine is a selective α1-adrenoceptor agonist primarily used as a decongestant.
Adrenergic Receptor  
Cancer   Viral Infection   Depression   Cardiovascular Disease   Obesity  
35
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
JAK   STAT   Interleukin Related   IFNAR  
Systemic Lupus Erythematosus   Psoriasis   Inflammatory Bowel Disease  
35
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
32
HY-N0142 Phloretin
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM，respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
SGLT   Endogenous Metabolite   GLUT  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Rheumatoid Arthritis  
29
HY-116771A CL 316243
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors.CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence.
Adrenergic Receptor  
Depression   Glucose Metabolism   Obesity  
28
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
26
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-19331 WZB117
WZB117 is a glucose transporter 1 (Glut1) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.
GLUT  
Digestive System Disease   Lung Cancer   Breast Cancer   Digestive System Inflammation  
22
HY-17498 Atenolol
Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
Adrenergic Receptor  
Cancer   Metabolic or Endocrine Disease   Depression   Alzheimer's Disease   Hypertension  
21
HY-P0118A Disitertide TFA
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer.
TGF-beta/Smad   PI3K   Apoptosis  
Cancer  
19
HY-P0118 Disitertide
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer.
TGF-beta/Smad   PI3K   Apoptosis  
Cancer  
19
HY-P0118B Disitertide diammonium
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer.
TGF-beta/Smad   PI3K   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
19
HY-N0164 Matrine
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI).
PINK1/Parkin   Opioid Receptor   Autophagy   Mitophagy   Ferroptosis   Apoptosis  
Lung Cancer   Liver Cancer   Depression   Pain   Digestive System Inflammation   Parkinson's Disease  
19
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
19
HY-N0143 Phlorizin
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities.
PI3K   Caspase   STAT   SGLT   NF-κB   GLUT   Bacterial   Akt   DNA/RNA Synthesis   JAK   Apoptosis   mTOR  
Cancer   Infection   Neurological, Eye or Ear Disease   Glucose Metabolism   Obesity  
17
HY-N0001 (-)-Epicatechin
(-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.
COX   Ferroptosis   Endogenous Metabolite  
Leukemia/Lymphoma/Myeloma   Depression   Pain   SARS-CoV-2 Infection   Lung Fibrosis   Rheumatoid Arthritis  
15
HY-N0378 D-Mannitol
D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells. D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed.
Environmental Pollutants   PGC-1α   Apoptosis   Adrenergic Receptor   Endogenous Metabolite   PKA  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity  
15
HY-N2037 Higenamine
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases.
MAP3K   MDM-2/p53   Adrenergic Receptor   ROS Kinase   Apoptosis  
Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
10
HY-P2565 Pepinh-TRIF TFA
Pepinh-TRIF (TFA) is a 30 aa peptide that blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with TLR-TRIF interaction.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
10
HY-107780A Cyclic-di-GMP sodium
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780 Cyclic-di-GMP
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780B Cyclic-di-GMP diammonium
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
STING   Endogenous Metabolite  
Cancer   Bacterial Infection  
9
HY-110382 Cyclic-di-GMP disodium
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
STING   Endogenous Metabolite  
9
HY-13295 Vinpocetine
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
Sodium Channel   IKK   Phosphodiesterase (PDE)  
Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Liver Cancer   Cardiovascular Disease   Alzheimer's Disease  
8
HY-N0002 (-)-Epicatechin gallate
(-)-Epicatechin gallate (Epicatechin gallate) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 7.5 μM. (-)-Epicatechin gallate is a GLUT1 and GLUT5 inhibitor. (-)-Epicatechin gallate decreases cell growth of GLUT5-expressing hxt0 yeast cells.
COX   Autophagy   Virus Protease   GLUT  
Cancer   Digestive System Disease   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Rheumatoid Arthritis  
7
HY-D1063 IR-780
IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC).
Fluorescent Dye   Apoptosis   Reactive Oxygen Species (ROS)  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-145597 KL-11743
KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis.
GLUT   Disulfidptosis  
Digestive System Disease   Lung Cancer   Digestive System Inflammation   Glucose Metabolism  
6
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
6
HY-147124 RIG012
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
IFNAR  
Cancer   Infection  
6
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
5
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
5
HY-19939S VX-984
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium.
DNA-PK  
4
HY-P99129 Anti-Mouse CD8a Antibody (53-6.7)
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice.

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
4
HY-116522 AR420626
AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca2+ signal-mediated glucose uptake and improve diabetes.
Free Fatty Acid Receptor   Histone Methyltransferase   HDAC   mTOR   CaMK   p38 MAPK   Epigenetic Reader Domain   GLUT   nAChR   TNF Receptor  
Lung Cancer   Breast Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease  
4
HY-P99168 Anifrolumab
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Species: Human

IFNAR  
Systemic Lupus Erythematosus   Rheumatoid Arthritis  
4
HY-P81169A PD-1 Antibody(YA3401)
PD-1 Antibody(YA3401) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

4
HY-P99048A Sintilimab (Anti-PD-1)
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Lung Squamous Cell Carcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
3
HY-P1812A AUNP-12 TFA
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Cancer  
3
HY-P1812 AUNP-12
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer  
3
HY-P990824 Anti-Mouse PD-1 Antibody (J43)
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer.

Species: Mouse

PD-1/PD-L1  
Breast Cancer   Prostate Cancer  
3
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Apoptosis   p38 MAPK  
Melanoma  
3
HY-N6871 Abietic acid
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis.
Bacterial   IKK   Ferroptosis  
Inflammation or Immune System Disease   Lung Cancer   Prostate Cancer   Liver Cancer   Bacterial Infection   Obesity  
3
HY-33549 α-Methyl-p-tyrosine
α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases.
Tyrosine Hydroxylase  
Cancer   Neurological, Eye or Ear Disease  
3
HY-164992 Trastuzumab vedotin
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
Antibody-Drug Conjugates (ADCs)   EGFR   Microtubule/Tubulin  
Gastric Cancer   Metastatic Breast Cancer   Urothelial Cancer  
3
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-P9981 Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Species: Human

Apoptosis  
Cancer   Inflammation or Immune System Disease  
2
HY-P99275 Patritumab
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

Species: Human

EGFR   Akt   ERK   PARP   Survivin  
Gastric Cancer   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer  
2
HY-141601 Telisotuzumab vedotin
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.
Antibody-Drug Conjugates (ADCs)   c-Met/HGFR   Microtubule/Tubulin  
Non-Small Cell Lung Cancer  
2
HY-P99843 Datopotamab
Datopotamab is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.

Species: Human

TROP2   ADC Antibodies  
Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-141598 Datopotamab deruxtecan (solution)
Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab (HY-P99843) and the toxic molecule-linker conjugate Deruxtecan (HY-13631E). Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer.
TROP2   Antibody-Drug Conjugates (ADCs)   Topoisomerase  
Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
2
HY-159194 DSPE-PEG2000-Cy5.5
DSPE-PEG2000-Cy5.5 is a phospholipid-fluorophore conjugate consisting of Cy5.5 covalently linked to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), serving as a surface label for liposomes in multimodal CT/optical imaging.DSPE-PEG2000-Cy5.5 can be used for the research of non-small cell lung cancer.
Liposome  
Non-Small Cell Lung Cancer  
1
HY-N10497 Dihydro-β-erythroidine
Dihydro-β-erythroidine is a a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced.
nAChR  
Neurological, Eye or Ear Disease  
1
HY-P11143 IL4RPep-1
IL4RPep-1 is an interleukin-4 receptor (IL-4R) binding agent. IL4RPep-1 preferentially binds to cells with high levels of IL-4R expression compared to those with low levels of expression. IL4RPep-1-labeled liposomes containing Doxorubicin (HY-15142A) are internalized by cells more efficiently. IL4RPep-1-labeled liposomes accumulate more effectively within H226 tumors.
Interleukin Related   Liposome  
Lung Cancer  
1
HY-P11143A IL4RPep-1 acetate
IL4RPep-1 acetate is an interleukin-4 receptor (IL-4R) binding agent. IL4RPep-1 acetate preferentially binds to cells with high levels of IL-4R expression compared to those with low levels of expression. IL4RPep-1 acetate-labeled liposomes containing Doxorubicin (HY-15142A) are internalized by cells more efficiently. IL4RPep-1 acetate-labeled liposomes accumulate more effectively within H226 tumors.
Interleukin Related   Liposome  
Lung Cancer  
1
HY-N9447 Norbergenin
Norbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming. Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis.
Free Radical Scavengers   Tyrosine Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   NF-κB   p38 MAPK   STAT  
Inflammation or Immune System Disease   Peptic Ulcer Disease   Arthritis   Alzheimer's Disease  
1
HY-P10908 H-20
H-20 is a PD-1 agonist. H-20 can be used in the research of chronic pain.
PD-1/PD-L1  
Lung Cancer  
1
HY-N0429 Diosbulbin B
Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC).
Apoptosis   MDM-2/p53   Bcl-2 Family   CDK  
Respiratory Disease   Breast Cancer   Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   Non-Small Cell Lung Cancer  
1
HY-N0460 1-Caffeoylquinic acid
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the Inhibitor for PD-1/PD-L1.
NF-κB   PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Parkinson's Disease   Obesity  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-N0910 Notoginsenoside Ft1
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8+ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance.
PI3K   mTOR   Akt   Apoptosis   p38 MAPK   ERK   Transmembrane Glycoprotein   Glutathione Reductase (GR)   Estrogen Receptor/ERR   Calcium Channel   Ferroptosis   G protein-coupled Bile Acid Receptor 1   FXR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
1
HY-D2208 SYTM Green
SYTM Green is a cell impermeant DNA dye that fluoresces green by binding to dsDNA (Ex/Em=503/530 nm). SYTM Green can also be used to stain bacteria, including Gram-positive and Gram-negative bacteria. Note: SYTM Green cannot penetrate living cells, and this product is equivalent to (Ex/Em=488/530 nm).
Fluorescent Dye  
1
HY-P5133 Synstatin (92-119)
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma.
Integrin  
Cancer  
1
HY-W013407 α-Methyltyrosine methyl ester hydrochloride
α-Methyltyrosine methyl ester hydrochloride is an orally active and competitive tyrosine hydroxylase inhibitor. α-Methyltyrosine methyl ester hydrochloride can inhibit the conversion of tyrosine to dopamine. α-Methyltyrosine methyl ester hydrochloride causes kidney damage and urethral calculi in rats. α-Methyltyrosine methyl ester hydrochloride can be used as a tool for sympathetic nervous system research.
Tyrosine Hydroxylase   Thyroid Hormone Receptor  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
1
HY-113100 N-Acetylputrescine hydrochloride
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Lung Cancer   Parkinson's Disease  
1
HY-W016409 Ethyl 3,4-dihydroxybenzoate
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   NO Synthase   Autophagy   Apoptosis  
Metabolic or Endocrine Disease  
1
HY-P990203 Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32)
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis.

Species: Mouse

Integrin  
Ulcerative Colitis  
1
HY-W342604 N-Acetylputrescine
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Parkinson's Disease  
1
HY-W179181 MSNBA
MSNBA is a potent and selective GLUT5 fructose transport inhibitor with an IC50 of 0.10 mM. MSNBA does not affect the transport activity of human GLUT1, GLUT2, GLUT3, GLUT4 or bacterial GlcPSe. MSNBA competitively inhibits GLUT5 fructose uptake with a Ki of 3.2 μM in MCF7 cells. MSNBA can be used for the study of cancer or diabetes.
GLUT  
Cancer   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Glucose Metabolism  
1
HY-N0755 Rhoifolin
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines.
Insulin Receptor   GLUT   NF-κB   p38 MAPK   Autophagy  
Lung Cancer   Pancreatic Cancer   Neurodegenerative Disease   Pain   Digestive System Inflammation   Glucose Metabolism  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-P99269 Sibrotuzumab
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).

Species: Human

FAP  
Colorectal Cancer   Non-Small Cell Lung Cancer  
1
HY-P990876 Afimkibart
Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease.

Species: Human

TNF Receptor   NF-κB   IFNAR  
Inflammatory Bowel Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-K0351 Human CD8+ T Cells Negative Selection Kit

MCE Human CD8+ T Cells Negative Selection Kit is designed to isolate CD8+ T cells from human peripheral blood mononuclear cells (PBMCs).

Cell Biology Cell Isolation

1
HY-171191 REGN5093-M114
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528).
Antibody-Drug Conjugates (ADCs)   Microtubule/Tubulin   c-Met/HGFR  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-142283 Dosimertinib
Dosimertinib-d3-d3 is a potent and orally active EGFR inhibitor. Dosimertinib-d3-d3 decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d3-d3 shows antiproliferative and anti-tumor activity. Dosimertinib-d3-d3 has the potential for the research of non-small-cell lung cancer (NSCLC).
Isotope-Labeled Compounds   EGFR  
/
HY-50895G Gefitinib (GMP)
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor.
EGFR   Autophagy   Apoptosis  
/
HY-103048 PD-1/PD-L1-IN 3
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-168968S ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC50 values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity.
EGFR   Histone Demethylase  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-12215S2 Deulorlatinib
Deulorlatinib (compound A), a deuterated derivative of Lorlatinib (HY-12215), is a potent inhibitor of tyrosine kinase demonstrating the potential for the research of ALK-positive advanced NSCLC.
Isotope-Labeled Compounds  
Cancer  
/
HY-B1440R Ethaverine hydrochloride (Standard)
Ethaverine hydrochloride (Standard) is the analytical standard of Ethaverine hydrochloride (HY-B1440). This product is intended for research and analytical applications. Ethaverine hydrochloride is a Papaverine derivative and vasodilator. Ethaverine hydrochloride inhibits Phosphodiesterase, Tyrosine hydroxylase, and MAO-B. Ethaverine hydrochloride blocks L-type Ca2+ channels, reduces intracellular Ca2+ levels, inhibits platelet adhesion and aggregation, regulates cardiac conduction and heart rate, and increases peripheral and cerebral blood flow. Ethaverine hydrochloride alters cochlear microcirculation, intracochlear Po2, CM potential, and EP in guinea pigs, and induces transient hypotension. Ethaverine hydrochloride is used in the research of peripheral vascular diseases.
Reference Standards   Drug Derivative   Phosphodiesterase (PDE)   Calcium Channel   Tyrosine Hydroxylase   Monoamine Oxidase  
Hypotension   Platelet Disease  
/
HY-N1255A Scoulerine hydrochloride
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine hydrochloride mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine hydrochloride effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine hydrochloride also exhibits multiple pharmacological activities including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine hydrochloride is applicable to research related to leukemia, ovarian cancer, and colorectal cancer.
Apoptosis   PI3K   Akt   mTOR   Adrenergic Receptor   GABA Receptor   Beta-secretase   Bcl-2 Family  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-DP99144F1 Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled
Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled, is an Anti-Mouse PD-1 Antibody (RMP1-14) (HY-P99144) derivative carrying dye CY7 (HY-D0825). Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.
PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-12292G IM-12 (GMP)
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
NF-κB   STAT   GSK-3   β-catenin   Bcr-Abl  
Leukemia/Lymphoma/Myeloma  
/
HY-128393S2 Trilinolein-d5
Trilinolein-d5 is the deuterium labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer.
Isotope-Labeled Compounds   ERK   MEK   Apoptosis   Akt   PI3K   MMP   E-Selectin  
/
HY-P5745 TYVPANASL
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine.
Transmembrane Glycoprotein  
Cancer  
/
HY-N17684 Abietatriene-3β-ol
Abietatriene-3β-ol is an anticancer agent. Abietatriene-3β-ol can be isolated from leaves of Thuja orientalis L. Abietatriene-3β-ol exhibits anticancer activity against non-small cell lung adenocarcinoma, ovarian cancer cells, skin melanoma, and colon cancer.
Others  
Colorectal Cancer   Melanoma   Ovarian Cancer   Non-Small Cell Lung Cancer  
/
HY-172733S PRMT5-MTA-IN-3-d3
PRMT5-MTA-IN-3-d3 (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d3 is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d3 has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC50 values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d3 has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer.
Isotope-Labeled Compounds   Histone Methyltransferase  
/
HY-P11255 SPDI-48-T1
SPDI-48-T1 is a lysine-stapled peptide. SPDI-48-T1 exhibits discernible binding affinities for MDM2 and MDMX, with Kd values of 396 nM and 456 nM, respectively. SPDI-48-T1 exhibits anticancer activity against breast cancer, colorectal cancer, non-small cell lung cancer, cervical cancer, and malignant melanoma.
MDM-2/p53  
Cancer  
/
HY-P11903 dTBP-3
dTBP-3 is a fully D-configured polypeptide competitive inhibitor that targets TIGIT. dTBP-3 can competitively occupy the binding interface between TIGIT and its ligand PVR, block TIGIT-mediated immunosuppressive signals, and reverse the immune exhaustion of NK cells and CD8+ T cells. dTBP-3 possesses anti-proteolytic activity and tumor tissue penetration ability, and can also enhance the tumor penetration capacity and cellular internalization efficiency of nanocarriers. dTBP-3 can be used in studies related to liver cancer, triple-negative breast cancer and non-small cell lung cancer.
Transmembrane Glycoprotein   Drug Intermediate  
Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-N18236 3β-Acetoxyl-atractylenolide I
3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
Histone Demethylase  
Breast Cancer   Prostate Cancer   Gastric Cancer   Bladder Cancer   Acute Myeloid Leukemia   Esophageal Cancer  
/
HY-16508S Ulipristal acetate-d6
Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma.
Isotope-Labeled Compounds   Progesterone Receptor   Autophagy  
Cancer   Metabolic or Endocrine Disease  
/
HY-138794G XL177A (GMP)
XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections.
Deubiquitinase   SARS-CoV   Histone Demethylase  
/
HY-N0460R 1-Caffeoylquinic acid (Standard)
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the inhibitor for PD-1/PD-L1.
Reference Standards   NF-κB   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-15947G Ravoxertinib (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
ERK   c-Myc   Hexokinase   Lactate Dehydrogenase  
Breast Cancer   Ovarian Cancer   Squamous Cell Carcinoma  
/
HY-P10838 PL120131
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors.
PD-1/PD-L1   Apoptosis  
Breast Cancer  
/
HY-P10542 Dodecapeptide AR71
Dodecapeptide AR71 is an inhibitor of melanoma inhibitory activity (MIA). Dodecapeptide AR71 can reduce cell migration, reduce metastasis formation, and increase immune response. Dodecapeptide AR71 can be used in research on the treatment of malignant melanoma.
Others  
Cancer  
/
HY-145771 PD-1/PD-L1-IN-20
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.
PD-1/PD-L1  
Cancer  
/
HY-N17888 Ephemeranthol A
Ephemeranthol A is a phenanthrene compound with anticancer and anti-inflammatory activities. Ephemeranthol A exerts significant anti-inflammatory effects in macrophages by inhibiting the NF-κB and MAPK signaling pathways. Ephemeranthol A induces apoptosis and inhibits metastasis of lung cancer cells by suppressing the FAK/Akt signaling and EMT processes. Ephemeranthol A can be used for the research of acute and chronic inflammatory diseases and non-small cell lung cancer.
NF-κB   p38 MAPK   FAK   Akt   Apoptosis   NO Synthase   COX   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P992024 SK48-E26
SK48-E26 is a human interleukin-1β (IL-1β) inhibitor, with a IC50 of 400 pM against human IL-1β, a IC50 of 185 pM against cynomolgus monkey IL-1β, and a Ka value ranging from 0.048 nM to 3 nM for human IL-1β. SK48-E26 binds to the conformational epitope of human IL-1β spanning amino acid residues 95-101, and blocks the biological activity of IL-1β. SK48-E26 can be used in research related to IL-1β-mediated inflammatory diseases and osteoarthritis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Arthritis  
/
HY-P991620 JS006
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-N9382 Gnidimacrin
Gnidimacrin is a protein kinase C (PKC) activator. Gnidimacrin inhibits cell growth of human leukemias, stomach cancers and non-small cell lung cancers in vitro, and shows activity against murine leukemias and solid tumors in vivo. Gnidimacrin can be used for leukemias, stomach cancers and non-small cell lung cancers research.
PKC  
Gastric Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-P11852 NOTA-cRY9M
NOTA-cRY9M is a reagent targeting FGFR1 with a Kd value of 58 nM, and exhibits subtype selectivity for FGFR2-4. When radiolabeled as [68Ga]Ga-NOTA-cRY9M, it functions as a stabilizer, imaging contrast enhancer, and tumor-targeting agent, and accumulates in FGFR1-positive non-small cell lung cancer xenograft models. NOTA-cRY9M can be used in studies related to non-small cell lung cancer.
FGFR  
Non-Small Cell Lung Cancer  
/
HY-B0076S Bisoprolol-d7 hemifumarate
Bisoprolol-d7 (hemifumarate) is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective type β1 adrenergic receptor blocker.
Adrenergic Receptor  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W778057 Ethyl 3,4-Dihydroxybenzoate-13C3
Ethyl 3,4-Dihydroxybenzoate-13C3 (Protocatechuic acid ethyl ester-13C3) is the 13C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
Reactive Oxygen Species (ROS)  
/
HY-W145552 4-Methoxyphenyl 3-O-allyl-β-D-galactopyranoside
4-Methoxyphenyl 3-O-Allyl-β-D-galactopyranoside is an organic compound belonging to the family of galactopyranosides. It is often used as a building block for the synthesis of more complex glycosides and glycoconjugates. 4-Methoxyphenyl 3-O-Allyl-β-D-galactopyranoside has various applications in biochemical research, especially in the study of carbohydrate metabolism and protein-carbohydrate interactions. This compound contains an allyl protecting group that can be selectively removed using palladium-catalyzed conditions to reveal hydroxyl functionality for further chemical modification.
Biochemical Assay Reagents  
/
HY-P5810 Ceratotoxin-2
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC50s of 8 nM and 88 nM against Nav1.2/β1 and Nav1.3/β1, respectively.
Sodium Channel  
Neurological, Eye or Ear Disease  
/
HY-P10982 SjDX5-53
SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatory T cells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P10978 NK224
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide (68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC).
PD-1/PD-L1  
/
HY-P11824 CoA-C2-SGRGK-cCPP
CoA-C2-SGRGK-cCPP is a NatD (NAA40) bisubstrate inhibitor with an IC50 of 78 nM and a Ki of 39 nM. CoA-C2-SGRGK-cCPP competitively targets the peptide substrate binding site and noncompetitively targets the CoA binding site of NatD to block acetyltransferase activity. CoA-C2-SGRGK-cCPP reduces cellular Nα-acetylation on histone H4, modulates EMT marker expression. CoA-C2-SGRGK-cCPP can be used for the research of non-small cell lung cancer.
Histone Acetyltransferase  
Non-Small Cell Lung Cancer  
/
HY-N12537A (2R,3S)-PD-1/PD-L1-IN-38
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1.
Aryl Hydrocarbon Receptor   PD-1/PD-L1  
Cancer  
/
HY-N18316 (2"S)-6"-Methyl-2",3"-Dihydrodelicaflavone
(2''S)-6''-Methyl-2'',3''-Dihydrodelicaflavone is a biflavonoid compound present in the whole herb of Selaginella doederleinii. (2''S)-6''-Methyl-2'',3''-Dihydrodelicaflavone exhibits antiproliferative activity against non-small cell lung cancer cells (IC50 = 3.1-6.8 μM) with low cytotoxicity toward normal cells. (2''S)-6''-Methyl-2'',3''-Dihydrodelicaflavone can be used in studies related to non-small cell lung cancer.
Others  
Non-Small Cell Lung Cancer  
/
HY-P1813 PSA1 (141-150)
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
Prostaglandin Receptor  
/
HY-N2513R β-Boswellic acid (Standard)
β-Boswellic acid (Standard) is the analytical standard of β-Boswellic acid. This product is intended for research and analytical applications. β-Boswellic acid is isolated from the gum resin of Boswellia serrata. β-Boswellic acid is a nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells.
Reference Standards   Lipoxygenase   DNA/RNA Synthesis  
Cancer  
/
HY-N11912 Soladulcoside A
Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC).
Biochemical Assay Reagents  
/
HY-P992405 MEDI-3185
MEDI-3185 is a potent CXCR4 antagonist. MEDI-3185 binds CXCR4 via CDR3H and ECL2 β-strand/β-strand interaction, blocks SDF-1 access and displaces SDF-1. MEDI-3185 can be used for the research of hematologic tumors, ovarian tumors.

Species: Human

CXCR  
Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-B0793G AZ-5104 (GMP)
AZ-5104 GMP is a GMP-grade form of AZ-5104 (HY-B0793). AZ-5104 is an orally active RORγ receptor-active compound, and also a circulating metabolite of AZD9291. AZ-5104 inhibits sensitizing EGFR mutants, EGFRT790M drug-resistant EGFR mutants and wild-type EGFR, while showing no activity against the IGF-1R family. AZ-5104 can be used in the research of non-small cell lung cancer.
ROR   EGFR   IGF-1R  
Non-Small Cell Lung Cancer  
/
HY-P3430 JM3A
JM3A is a highly specific peptoid reagent that targets newly appears cell surface vimentin (CSV) on tumor-transformed early lung cancer cells. JM3A can detect and stain CSV by coupling with fluorophores.
Biochemical Assay Reagents  
/
HY-W062109S Olopatadine-d6
Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease  
/
HY-P10826 PD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model.
PD-1/PD-L1  
Cancer  
/
HY-129223A 28-O-Tigloylgymnemagenin
28-O-Tigloylgymnemagenin (I) is a natural anticancer agent. 28-O-Tigloylgymnemagenin has good anti-proliferation activity on human acute myeloid leukemia cells and non-small cell lung cancer (NSCLC). 28-O-Tigloylgymnemagenin can be used for the study of leukemia and lung cancer.
Drug Derivative  
Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-B0437S Sotalol-d6
Sotalol-d6 is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent.
Isotope-Labeled Compounds   Adrenergic Receptor   Potassium Channel  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-152852S Mefatinib-d6 free base
Mefatinib-d6 free base (Mifanertinib-d6) is the 6-labeled Mefatinib free base (HY-152852). Mefatinib free base is an orally active EGFR and HER2 kinase inhibitor with IC50 values of 0.4 nM and 11.7 nM, respectively. Mefatinib free base inhibits tumor growth in mouse models of lung cancer xenografts that overexpress EGFR/HER2, carry EGFR mutations, or carry Erlotinib (HY-50896)-resistant EGFR double mutations. Mefatinib free base can be used for the research of advanced EGFR-mutant non-small cell lung cancer.
Isotope-Labeled Compounds   EGFR  
Non-Small Cell Lung Cancer  
/
HY-B0426AS2 Olopatadine-d6 hydrochloride
Olopatadine-d6 (ALO4943A-d6; KW4679-d6) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease  
/
HY-176344S PD1, Arg-13C6,15N4, Lys-13C6,15N2
PD1, Arg-13C36, 15N4, Lys-13C6, 15N2 is the 13C- and 15N-labeled PD1.
Isotope-Labeled Compounds  
Cancer  
/
HY-W654256 Matrine-d3
Matrine-d3 (Matridin-d3) is a deuterium labeled Matrine (HY-N0164). Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI).
Isotope-Labeled Compounds   Autophagy   Apoptosis   Opioid Receptor   Ferroptosis   PINK1/Parkin   Mitophagy  
Inflammation or Immune System Disease  
/
HY-N20707 Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
PARP   Topoisomerase   Penicillin-binding protein (PBP)   PD-1/PD-L1   Bacterial   Parasite  
Cancer   Bacterial Infection   Leishmania Infection  
/
HY-W016409R Ethyl 3,4-dihydroxybenzoate (Standard)
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
Reference Standards   HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   NO Synthase   Autophagy   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-P10386 155H1
155H1 (Compound 11) is a stapled peptide, that covalently binds hMcl1 (172-323) with IC50 of 18 nM.
Bcl-2 Family  
Cancer  
/
HY-N12041 Axl-IN-16
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression.

Source: Hericium erinaceus,Monascus

TAM Receptor   HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-N18315 (2''S)-2'',3''-Dihydrodelicaflavone
(2''S)-2'',3''-Dihydrodelicaflavone is a biflavonoid compound present in the whole herb of Selaginella doederleinii, which exhibits antiproliferative and apoptosis-inducing activities against non-small cell lung cancer cells. (2''S)-2'',3''-Dihydrodelicaflavone can be used in the research of non-small cell lung cancer.
Apoptosis   Caspase   IAP   Survivin  
Non-Small Cell Lung Cancer  
/
HY-13295S Vinpocetine-d5
Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
Isotope-Labeled Compounds   Sodium Channel   IKK   Phosphodiesterase (PDE)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P11110 RK-10
RK-10 is a PD-L1 binding peptide. RK-10 conjugated with Cy5 (HY-D0821) or Biotin (HY-B0511) can used to detect PD-L1 expressing tumors with flow cytometry or immunohistochemistry. RK-10 can be used for cancers like NSCLC, breast cancer, squamous cell carcinoma and melanoma detection research.
PD-1/PD-L1  
/
HY-15772GL Osimertinib (GMP Like)
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
EGFR   Apoptosis   Ferroptosis  
Cancer  
/
HY-15772G Osimertinib (GMP)
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
EGFR   Apoptosis   Ferroptosis  
Cancer  
/
HY-P991867 SHR-1707
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Amyloid-β  
Alzheimer's Disease  
/
HY-158186S Bisoprolol-d6 hemifumarate
Bisoprolol-d6 fumarate is deuterium labeled Bisoprolol (hemifumarate). Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
Isotope-Labeled Compounds   Adrenergic Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-125723 Echinocandin B
Echinocandin B (SL 7810) is a lipopeptide antifungal antibiotic. Echinocandin B is produced by Aspergillus nidulans. Echinocandin B inhibits β-1,3-glucan activity, thereby blocking the biosynthesis of fungal cell walls. Echinocandin B exhibits activity against a variety of Aspergillus species.

Source: Aspergillus nidulans var echinulatus

Endogenous Metabolite   Antibiotic   Fungal  
Aspergillus Infection  
/
HY-P11856 cPP12-2-Lys
cPP12-2-Lys is a cyclic cell-penetrating peptide that serves as a negative control, i.e., it lacks any NatD bisubstrate moiety. cPP12-2-Lys is not a NatD inhibitor (IC50 = 9500 nM), but it possesses excellent cell-penetrating ability and can mediate the entry of conjugated bisubstrate inhibitors into non-small cell lung cancer (NSCLC) cells. cPP12-2-Lys can be used in NSCLC research.
Histone Acetyltransferase  
Non-Small Cell Lung Cancer  
/
HY-B0426AR Olopatadine hydrochloride (Standard)
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Reference Standards   Histamine Receptor   CXCR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10630 Pep63
Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-P11089 TP53 neoepitope
TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8+ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
MHC  
/
HY-P10593 Influenza A NP (383-391) (HLA-B27)
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research.
Transmembrane Glycoprotein   Influenza Virus  
/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

CD73   TNF Receptor   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-P11932 FGLP21
FGLP21 is a polypeptide targeting FGL1. FGLP21 has a simulated binding affinity of -9.56 kcal/mol for FGL1, and inhibits the binding of 68Ga-NODA-FGLP21 to FGL1 in a competitive binding assay using FGL1-positive Huh7 cells, with an IC50 of 101.0 nM. FGLP21 preferentially binds to FGL1-positive Huh7 cells, and excess unlabeled FGLP21 can significantly block the uptake of 68Ga-NODA-FGLP21 in Huh7 xenograft tumors. FGLP21 can be used for FGL1-targeted tumor imaging and immune checkpoint research.
Biochemical Assay Reagents  
Cancer  
/
HY-P5502 Influenza NP (311-325)
Influenza NP (311-325) is a biologically active peptide derived from the influenza virus nucleoprotein (NP). The NP protein is an MHC class II restricted epitope that elicits host immune responses during viral infection. Influenza NP (311-325) elicits the most potent interferon gamma (IFN-γ) production without stimulating CD8 T cells in mice.
Influenza Virus  
/
HY-167925S 2'-O-Methyl Uridine-d3
2'-O-Methyl Uridine-d3 is the deuterium labeled Rec 15/2615 (HY-167925). Rec 15/2615 is a potent α(1)-adrenergic agonist that stimulates small cholangiocyte proliferation through the activation of calcium-dependent signaling pathways.
Isotope-Labeled Compounds   Adrenergic Receptor   Calcium Channel  
Metabolic or Endocrine Disease  
/
HY-P991612 S095024
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies.

Species: Human

CD73  
Inflammation or Immune System Disease   Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-N2104 Daurinoline
Daurinoline is an alkaloid that can be isolated from the roots of Menispermum dauricum. Daurinoline may be a potential anti-tumor agent or chemosensitizer for chemo-resistant NSCLC research.
Others  
/
HY-N12537 PD-1/PD-L1-IN-38
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8+ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity.
PD-1/PD-L1  
/
HY-W707407 Bisoprolol-d7
Bisoprolol-d7 is deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
Isotope-Labeled Compounds   Adrenergic Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-165394 Melafolone
Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research.
COX   EGFR   PD-1/PD-L1   PI3K   Akt  
/
HY-126562R Piperlonguminine (Standard)
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent.
Reference Standards   Bacterial   Fungal   Antibiotic  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P992023 APX002
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis.

Species: Human

Interleukin Related  
Autoimmune Disease  
/
HY-P11280 PRAME peptide (425-433)
PRAME peptide (425-433) is a peptide corresponding to amino acids 425-433 of PRAME (preferentially expressed antigen) in melanoma. PRAME peptide (425-433) can be used to stimulate human PRAME-specific CD8+ T cells.
Others  
Cancer  
/
HY-P991654 SAR228810
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.

Species: Human

Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-P1385 TCS 183
TCS 183, a peptide, is a GSK-3β inhibitor. TCS 183 blocks GSK-3β autoinhibition and decreases the level of AMPK phosphorylation. TCS 183 can be used for neuropathological diseases, particularly Alzheimer’s disease, research.
GSK-3   p38 MAPK  
Neurological, Eye or Ear Disease  
/
HY-15244G Alpelisib (GMP)
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
PI3K   Apoptosis  
/
HY-129029S1 Bisoprolol-d5 fumarate (2:1)
Bisoprolol-d5 fumarate (2:1) is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
Isotope-Labeled Compounds   Adrenergic Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-12299G WH-4-023 (GMP)
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs.
Src  
Non-Small Cell Lung Cancer  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-N1420AS2 Rhamnose-13C-2 monohydrate
Rhamnose-13C-2 (monohydrate) is the 13C labeled Rhamnose monohydrate. Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies. Rhamnose monohydrate
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-17498S1 Atenolol-d6
Atenolol-d6 ((RS)-Atenolol-d6) is deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
Isotope-Labeled Compounds  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-121246S Fluorofenidone-d3
Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).
Isotope-Labeled Compounds   ACSL Family   NF-κB   ERK   TGF-beta/Smad  
Inflammation or Immune System Disease   Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P991801 Anti-Mouse IFN Beta Antibody (MIB-5E9.1)
Anti-Mouse IFN Beta Antibody (MIB-5E9.1) is an antibody targeting mouse IFN-β. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) blocks the IFN-β signaling pathway, abolishes LPS-induced upregulation of B7H1 and GITRL in dendritic cells, restores dendritic cell-dependent T cell proliferation impaired by LPS exposure, and reverses LPS-induced upregulation of PD-1 on splenic T cells. Anti-Mouse IFN Beta Antibody (MIB-5E9.1) reduces LPS-induced upregulation of GITR on splenic T cells and inhibits LPS-mediated Treg priming.

Species: Mouse

IFNAR   PD-1/PD-L1  
Cancer  
/
HY-128393S1 Trilinolein-13C54
Trilinolein-13C54 is the 13C-labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer.
Isotope-Labeled Compounds   E-Selectin   MEK   Akt   MMP   PI3K   Apoptosis   ERK  
Cancer  
/
HY-N13164 Polygalacin D3
Polygalacin D3 is a triterpenoid saponin compound that can be extracted from the roots of the balloon flower. Polygalacin D3 can inhibit the proliferation of non-small cell lung cancer (NSCLC) cell lines by blocking the PI3K/Akt pathway, and it induces cell cycle arrest and cell apoptosis.
PI3K   Akt   Apoptosis  
/
HY-16508S1 Ulipristal acetate-d3
Ulipristal acetate-d3 (CDB-2914-d3) is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma.
Isotope-Labeled Compounds   Autophagy   Progesterone Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-N2037R Higenamine (Standard)
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases.
Reference Standards   MAP3K   MDM-2/p53   Adrenergic Receptor   ROS Kinase   Apoptosis  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease   Bacterial Infection  
/
HY-114277S2 Sotorasib-d3
Sotorasib-d3 (AMG-510-d3) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC).
Isotope-Labeled Compounds   Ras  
/
HY-W005223R (R)-Tetrahydrofuran-2-carboxylic acid (Standard)
(R)-Tetrahydrofuran-2-carboxylic acid (Standard) is an analytical standard for (R)-Tetrahydrofuran-2-carboxylic acid (HY-W005223). This product is intended for research and analytical applications. (R)-Tetrahydrofuran-2-carboxylic acid is a chiral building block for Faropenem (HY-A0035). Faropenem is a clinically effective non-natural β-lactam antibiotic.
Reference Standards   Biochemical Assay Reagents   Drug Intermediate  
Infection  
/
HY-12857S2 Brigatinib-d11
Brigatinib-d11 (AP-26113-d11) is deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC.
Isotope-Labeled Compounds   Anaplastic lymphoma kinase (ALK)  
Cancer  
/
HY-B0426AS Olopatadine-d3 hydrochloride
Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W004206R 2-(4-Methoxyphenyl)acetic acid (Standard)
2-(4-Methoxyphenyl)acetic acid is a plasma metabolite, with high sensitivity and specificity value as a biomarker for discriminating between NSCLC and healthy controls.
Reference Standards   Endogenous Metabolite  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
Reference Standards   Apoptosis   p38 MAPK  
Melanoma  
/
HY-165645 Protectin D1-d5
Protectin D1-d5 (Neuopotecti D1-d5) is deuterium labeled Protectin D1.
Isotope-Labeled Compounds  
/
HY-184315 LDC8201
LDC8201 is a selective, orally active, covalent inhibitor that targets EGFR and Her2 exon 20 insertion mutants. LDC8201 induces tumor shrinkage and regression. LDC8201 is applicable to research related to non-small cell lung cancer carrying EGFR or Her2 exon 20 insertion mutations.
EGFR  
Non-Small Cell Lung Cancer  
/
HY-N3764 Diosbulbin C
Diosbulbin C is a diterpene lactone component, which can be extracted from traditional Chinese medicine Dioscorea bulbifera L.. Diosbulbin C possesses high anticancer activity in non-small cell lung cancer (NSCLC). Diosbulbin C could induce cell cycle arrest at G0/G1 phase in NSCLC. Diosbulbin C also inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS.
Dihydrofolate reductase (DHFR)   Akt   Endogenous Metabolite  
/
HY-159846S Luvometinib-d
Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.
Isotope-Labeled Compounds   MEK   p38 MAPK   Apoptosis  
Cancer  
/
HY-P2478A Human PD-L1 inhibitor V TFA
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-B0804S Nadolol-d9
Nadolol-d9 is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker.
Adrenergic Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-153939S Idasanutlin-d3-1
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
Isotope-Labeled Compounds   MDM-2/p53   E1/E2/E3 Enzyme   Apoptosis   Pyroptosis   Reactive Oxygen Species (ROS)   Caspase  
Musculoskeletal and Skin Disease   Colorectal Cancer   Melanoma   Neuroblastoma   Osteosarcoma   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma  
/
HY-B0437AS Sotalol-d6 hydrochloride
Sotalol-d6 (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels.
Adrenergic Receptor   Potassium Channel  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P4886 Amyloid β-Protein (3-42)
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42).
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-P1837 Influenza HA (518-526)
Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele Kd to form a complex, which is then recognized by specific CD8+ T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8+ T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza.
Influenza Virus   HSV  
Influenza Virus Infection   Respiratory Syncytial Virus Infection  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991635 PF-07329640
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research.

Species: Human

TNF Receptor  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-A0100R Thiamine monochloride (Standard)
Mebeverine (hydrochloride) (Standard) is the analytical standard of Mebeverine (hydrochloride). This product is intended for research and analytical applications. Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation.
Reference Standards   Endogenous Metabolite   Bacterial  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P991382 SAR-439459
SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .

Species: Human

TGF-β Receptor  
Cancer  
/
HY-116753 (-)Clausenamide
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).
Amyloid-β   Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-N1420AS Rhamnose-13C monohydrate
Rhamnose-13C (monohydrate) is the 13C labeled Rhamnose monohydrate. Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies. Rhamnose monohydrate c
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-103439 GW583340 dihydrochloride
GW 583340 dihydrochloride is an orally active ErbB-2/EGFR tyrosine kinase inhibitor. GW 583340 dihydrochloride exhibits antitumor activity in xenograft models with EGFR overexpression or ErbB-2 overexpression. GW 583340 dihydrochloride is applicable to research related to head and neck cancer, breast cancer, and gastric cancer.
Tyrosine Hydroxylase   EGFR  
Cancer  
/
HY-P991079 Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-127023 Eicosapentaenoyl serotonin
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms.
Endogenous Metabolite   FAAH   Interleukin Related   Tyrosine Hydroxylase  
Metabolic or Endocrine Disease  
/
HY-W106860 9H-Carbazole-3-carbaldehyde
9H-Carbazole-3-carbaldehyde (3-Formylcarbazole) is a carbazole compound and an anticancer agent. 9H-Carbazole-3-carbaldehyde is present in the stems of Clausena lansium (Lour.) Skeels. 9H-Carbazole-3-carbaldehyde can be used in the research of cervical cancer, leukemia, non-small cell lung cancer and liver cancer.
Drug Intermediate  
Liver Cancer   Cervical Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-129029S Bisoprolol-d5
Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
Isotope-Labeled Compounds   Adrenergic Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10762 Ricorfotide vedotin
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma).
Peptide-Drug Conjugates (PDCs)   Folate Receptor (FR)   TRP Channel  
Cancer  
/
HY-P2478 Human PD-L1 inhibitor V
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.
PD-1/PD-L1  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-161564 T4/OVA
T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P990778 Xirestomig
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1×4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs).

Species: Human

TNF Receptor   PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P99516 Vulinacimab
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer.

Species: Human

VEGFR  
Non-Small Cell Lung Cancer  
/
HY-P99551 Tosatoxumab
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992).

Species: Human

Antibiotic   Bacterial  
Staphylococcus Aureus Infection  
/
HY-113248R 3-Nitro-L-tyrosine (Standard)
3-Nitro-L-tyrosine (Standard) is the analytical standard of 3-Nitro-L-tyrosine (HY-113248). This product is intended for research and analytical applications. 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Reference Standards   Reactive Oxygen Species (ROS)   Endogenous Metabolite   Adrenergic Receptor  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-122958 Peucedanocoumarin III
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.
α-synuclein  
Parkinson's Disease  
/
HY-P991176 RG-6333
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).

Species: Human

CD19   CD28  
Cancer  
/
HY-P992159 Anti-ZnT8 Antibody (mAb43)
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes.

Species: Human

SLC39 (Zinc Transporter)  
Type 1 Diabetes  
/
HY-13295R Vinpocetine (Standard)
Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
Reference Standards   Sodium Channel   IKK   Phosphodiesterase (PDE)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-112870AS Firmonertinib-d3 mesylate
Firmonertinib-d3 (Alflutinib-d3) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.
Isotope-Labeled Compounds   EGFR  
Cancer   Inflammation or Immune System Disease  
/
HY-142283AS Dosimertinib-d5 mesylate
Dosimertinib-d5 (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d5 (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d5 (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC).
EGFR  
Lung Cancer  
/
HY-P99895 Rulonilimab
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P10862A AH-D peptide TFA
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P10582A SIYNFEKL TFA
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cell. SIYNFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.
MHC  
Inflammation or Immune System Disease  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-W062109 Olopatadine
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Histamine Receptor   CXCR  
Inflammation or Immune System Disease   Parkinson's Disease   Obesity  
/
HY-W115607 PEG4000-bis-amine
PEG4000-bis-amine (Poly(ethylene glycol)-bis-amine 4000) is a diamine-terminated polyethylene glycol that acts as a linker for conjugate synthesis. PEG4000-bis-amine facilitates the development of MUC1 aptamer-based near-infrared fluorescent probes, and also conjugates folic acid with the near-infrared dye ICG-Der-01 to form a tumor-targeting probe. PEG4000-bis-amine supports the synthesis of folic acid-PEG-DSPE conjugates for the preparation of folic acid-targeted biliposomes. PEG4000-bis-amine is widely used in studies related to breast cancer, non-small cell lung cancer, hepatocellular carcinoma, rheumatoid arthritis, and tumors with high folate receptor expression.
Biochemical Assay Reagents  
Cancer  
/
HY-113248S 3-Nitro-L-tyrosine-d3
3-Nitro-L-tyrosine-d3 is the deuterium labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Endogenous Metabolite  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P10087 Mouse TREM-1 SCHOOL peptide
Mouse TREM-1 SCHOOL peptide (Mouse TREM-1(213-221), GF9) targets the interaction between TREM-1 and its signaling partner DAP-12, specifically silencing the TREM-1 signaling pathway, regulate the production of TREM-1-mediated pro-inflammatory cytokines in vivo and in vitro. Mouse TREM-1 SCHOOL peptide has anti-tumor effects. Mouse TREM-1 SCHOOL peptide can reduce the formation of vitreoretinal neovascularization.
Others  
Inflammation or Immune System Disease   Lung Cancer  
/
HY-123468 HA-1004
HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models.
Cyclic GMP-AMP Synthase   Tyrosine Hydroxylase   ERK   PKA   Calcium Channel  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10634 P17 Peptide
P17 Peptide is a human TGF-β1 inhibitory peptide. P17 Peptide can block woodchuck TGF-β1 activity.
TGF-beta/Smad  
/
HY-113248S1 3-Nitro-L-tyrosine-13C6
3-Nitro-L-tyrosine-13C6 is the 13C labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Endogenous Metabolite  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-103048A PD-1/PD-L1-IN 3 TFA
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases.
PD-1/PD-L1  
/
HY-N1420AR Rhamnose monohydrate (Standard)
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
Reference Standards   Endogenous Metabolite   MMP   Interleukin Related   PKA  
Cancer   Infection   Metabolic or Endocrine Disease  
/
HY-P11107 RP-832c
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF).
Apoptosis   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P10581A SIIVFEKL TFA
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cells. SIIVFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.
MHC  
Inflammation or Immune System Disease  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-150058 Bocconoline
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD).
Others  
Neurological, Eye or Ear Disease  
/
HY-P2511 Insulin β Chain Peptide (15-23)
Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond.
Transmembrane Glycoprotein  
Metabolic or Endocrine Disease  
/
HY-114277S Sotorasib-d7
Sotorasib-d7 (AMG-510-d7) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC).
Isotope-Labeled Compounds   Ras  
/
HY-P99658 Imaprelimab
Imaprelimab is a humanized IgG1κ anti-CD146 antibody. Imaprelimab exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab can be used in studies related to brain metastasis of non-small cell lung cancer.

Species: Human

Transmembrane Glycoprotein  
Cerebrovascular Disease   Non-Small Cell Lung Cancer  
/
HY-P991078 Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P5453 CFP10 (71–85)
CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)
CD3  
/
HY-P10336 Serpinin
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function. Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects.
Serpin  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P990009 Nisevokitug
Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody and an inhibitor of the TGF-β signaling pathway. Nisevokitug blocks the binding of TGF-β to the membrane-bound TGF-βR1/TGF-βR2 receptors, inhibits both Smad-dependent and Smad-independent downstream cascade signaling, downregulates fibrosis-related genes, and reverses the TGF-β-mediated immunosuppressive microenvironment. Nisevokitug can be used in the research of diseases such as pancreatic ductal adenocarcinoma, colorectal cancer, myelofibrosis, and myelodysplastic syndrome.

Species: Human

TGF-beta/Smad   TGF-β Receptor  
Colorectal Cancer   Pancreatic Cancer  
/
HY-N3431 Kaempferol-7-O-rhamnoside
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure.
AMPK   PD-1/PD-L1   FXR   Reactive Oxygen Species (ROS)  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity  
/
HY-P991061 Tagmokitug
Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8+ T cell subsets. Tagmokitug can be used for the research of solid tumors.

Species: Human

CCR  
Cancer  
/
HY-W005223 (R)-Tetrahydrofuran-2-carboxylic acid
(R)-Tetrahydrofuran-2-carboxylic acid is a chiral building block for Faropenem (HY-A0035). Faropenem is a clinically effective non-natural β-lactam antibiotic.
Biochemical Assay Reagents   Drug Intermediate  
Infection  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-P99223 Tovetumab
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC).

Species: Human

PDGFR  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-P991336 Ordastobart
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.

Species: Human

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-N8321 5-O-Caffeoylshikimic acid
5-O-Caffeoylshikimic acid can be used in the study for NSCLC.
Others  
Non-Small Cell Lung Cancer  
/
HY-P990073 Davutamig
Davutamig (REGN-5093) is a human IgG4-kappa, anti-MET bispecific antibody. Davutamig binds 2 distinct epitopes of MET, blocking ligand binding and inducing MET internalization and degradation. Davutamig is applicable to the research of advanced non-small cell lung cancer with MET gene abnormalities.

Species: Human

c-Met/HGFR  
Non-Small Cell Lung Cancer  
/
HY-114491 Rineterkib
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
ERK   Raf  
/
HY-P99181 Mupadolimab
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.

Species: Human

CD73  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   SARS-CoV-2 Infection  
/
HY-B1440 Ethaverine hydrochloride
Ethaverine hydrochloride is a Papaverine derivative and vasodilator. Ethaverine hydrochloride inhibits Phosphodiesterase, Tyrosine hydroxylase, and MAO-B. Ethaverine hydrochloride blocks L-type Ca2+ channels, reduces intracellular Ca2+ levels, inhibits platelet adhesion and aggregation, regulates cardiac conduction and heart rate, and increases peripheral and cerebral blood flow. Ethaverine hydrochloride alters cochlear microcirculation, intracochlear Po2, CM potential, and EP in guinea pigs, and induces transient hypotension. Ethaverine hydrochloride is used in the research of peripheral vascular diseases.
Drug Derivative   Phosphodiesterase (PDE)   Calcium Channel   Tyrosine Hydroxylase   Monoamine Oxidase  
Hypotension   Platelet Disease  
/
HY-113418 Beta-Cortol
Beta-Cortol is an O-glycosylated compound and cortisol metabolite. It can be isolated from the leaves of mulberry cultivar Yu 711, and its concentration decreases significantly when the plant is subjected to drought stress. Beta-Cortol serves as a biomarker, as serum Beta-Cortol levels in early non-small cell lung cancer models are downregulated to 1/8 of the preoperative level after tumor resection. Due to such dramatic changes under specific pathological conditions, Beta-Cortol is currently widely used in studies related to early non-small cell lung cancer.
Endogenous Metabolite  
Non-Small Cell Lung Cancer  
/
HY-P991480 ONC-841
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease.

Species: Human

Transmembrane Glycoprotein   Tau Protein   Amyloid-β  
Cancer   Alzheimer's Disease  
/
HY-P99202 Vibostolimab
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P99114 Sugemalimab
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.

Species: Human

PD-1/PD-L1  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P991669 IGN523
IGN523 is an anti-CD98 antibody (hCD98, KD = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers..

Species: Human

Caspase   Apoptosis  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-137295 Ingenol 3,20-dibenzoate
Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells.
PKC   Apoptosis  
Neurological, Eye or Ear Disease   Respiratory Disease   Digestive System Disease   Digestive System Inflammation   Non-Small Cell Lung Cancer  
/
HY-W115752 Hydrazine sulfate (99%)
Hydrazine sulfate is an orally active PEPCK inhibitor. Hydrazine sulfate inhibits PEPCK and low-Km ALDH. Hydrazine sulfate impairs gluconeogenesis and enhances the protective effect of energy substrates against MPP+ toxicity. Hydrazine sulfate exacerbates liver damage in rats when combined with Ethanol. Hydrazine sulfate can be used in the research of shock, non-small cell lung cancer, colorectal cancer and Parkinson's disease.
PEPCK   Aldehyde Dehydrogenase (ALDH)  
Metabolic or Endocrine Disease   Lung Cancer   Colorectal Cancer   Salmonella Infection   Parkinson's Disease  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-113248 3-Nitro-L-tyrosine
3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
Endogenous Metabolite   Adrenergic Receptor   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-B0927 Hydrastine
Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage.
Tyrosine Hydroxylase   OAT   Dopamine Receptor  
Parkinson's Disease  
/
HY-W018597 2-Chloro-N-methylethanamine hydrochloride
2-Chloro-N-methylethanamine hydrochloride is a nitro compound that can be used to synthesize PD-1 inhibitors.
Biochemical Assay Reagents  
/
HY-17498S Atenolol-d7
Atenolol-d7 is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
Adrenergic Receptor  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-W020952 Palladium(Ⅱ) acetylacetonate
Palladium(II) acetylacetonate is a metal-organic complex. Palladium(II) acetylacetonate upregulates the expression of GRP78, ATF-4, XBP-1, CHOP, and phosphorylated c-Jun. Palladium(II) acetylacetonate induces Apoptosis. Palladium(II) acetylacetonate has anticancer effects against non-small cell lung cancer, gastric cancer, leukemia, and cervical cancer.
Biochemical Assay Reagents   HSP   Eukaryotic Initiation Factor (eIF)   IRE1   JNK   Apoptosis  
Cancer  
/
HY-P990717 Brenetafusp
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3+ T cells to kill PRAME+ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer.

Species: Human

CD3  
Cancer  
/
HY-P99128 Anti-Mouse CD8 beta Antibody (53-5.8)
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8+ T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology.

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
/
HY-P990569 CM-24
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-W004206 2-(4-Methoxyphenyl)acetic acid
2-(4-Methoxyphenyl)acetic acid is a plasma metabolite, with high sensitivity and specificity value as a biomarker for discriminating between NSCLC and healthy controls.
Endogenous Metabolite  
Lung Cancer  
/
HY-P990667 STX-100
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer.

Species: Human

Integrin   TGF-beta/Smad  
Cancer   Lung Fibrosis  
/
HY-B0426A Olopatadine hydrochloride
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Histamine Receptor   CXCR  
Inflammation or Immune System Disease   SARS-CoV-2 Infection   Parkinson's Disease   Obesity  
/
HY-P10944 Unlabeled FXX489
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC).
FAP  
Respiratory Disease   Breast Cancer   Non-Small Cell Lung Cancer  
/
HY-P990957 Ficerafusp alfa
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer.

Species: Human

EGFR   TGF-beta/Smad  
Inflammation or Immune System Disease   Colorectal Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Squamous Cell Carcinoma  
/
HY-113366 Prostaglandin J2
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD).
Prostaglandin Receptor   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P99961 Tifcemalimab
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer.

Species: Human

CD28  
Non-Small Cell Lung Cancer  
/
HY-P990254 Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4+ and CD8+ T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer.

Species: Mouse

CXCR  
Inflammation or Immune System Disease   Pancreatic Cancer  
/
HY-P99827 Cobolimab
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

Species: Human

Tim3  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-N1255 Scoulerine
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine also exhibits multiple pharmacological activities including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine is applicable to research related to leukemia, ovarian cancer, and colorectal cancer.
Bcl-2 Family   Apoptosis   mTOR   GABA Receptor   PI3K   Adrenergic Receptor   Beta-secretase   Akt  
Digestive System Disease   Lung Cancer   Digestive System Inflammation   Alzheimer's Disease  
/
HY-P990855 Anti-CD8α Antibody (OKT-8)
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8+ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).

Species: Human

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma  
/
HY-P990947 Tilatamig
Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).

Species: Human

ADC Antibodies   EGFR  
Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma  
/
HY-P99159 Ivuxolimab
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc.

Species: Human

Interleukin Related  
Prostate Cancer   Liver Cancer   Melanoma  
/
HY-107413 SR11237
SR11237 (BMS-649) GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease.
RAR/RXR   Tyrosine Hydroxylase  
Cancer  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-P990790 Anti-Mouse CD8α Antibody (2.43)
Anti-Mouse CD8α Antibody (2.43) is an anti-mouse CD8α IgG2b monoclonal antibody. Anti-Mouse CD8α Antibody (2.43) can significantly deplete CD8+ T cells. Anti-Mouse CD8α Antibody (2.43) can prolong the survival time of liver cell transplantation. Anti-Mouse CD8α Antibody (2.43) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Arthritis  
/
HY-P9964 Necitumumab
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer.

Species: Human

EGFR  
Colorectal Cancer   Non-Small Cell Lung Cancer  
/
HY-P5005 VIPhyb
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis.
CMV   PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-156002 LUNA18
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.
Ras   ERK  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-137677B GTPγS tetralithium
GTPγS (Guanosine 5'-[γ-thio]triphosphate) tetralithium is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS tetralithium to couple with G- protein α, to study its effect on kinase activity. GTPγS tetralithium acts as a component of lysis buffer.
GLUT  
Metabolic or Endocrine Disease  
/
HY-P990788 Anti-Mouse PD-1 Antibody (29F.1A12)
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-100355 C18-Ceramide (d18:1/18:0)
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P9997 Rosnilimab
Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-164789 Sacituzumab tirumotecan
Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer.
Antibody-Drug Conjugates (ADCs)   TROP2  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P10587 Icotrokinra
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Interleukin Related   STAT   IFNAR  
Inflammation or Immune System Disease  
/
HY-P70676 PD-1 Protein, Cynomolgus (HEK293, His)
PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P73341 PD-1 Protein, Canine (HEK293, Fc)
Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. PDCD1 plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but PDCD1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P78191 PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P73342 PD-1 Protein, Canine (HEK293, His, solution)
Programmed cell death protein 1 (Pdcd1) is an immune-inhibitory receptor which delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2, playing a critical role in induction and maintenance of immune tolerance to self. Pdcd1plays a role in anti-tumor immunity and is involved in safeguarding against autoimmunity, but Pdcd1-mediated inhibitory pathway is also exploited by tumors to attenuate anti-tumor immunity. PD-1 Protein, Canine (HEK293, His, solution) is the recombinant canine-derived PD-1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P73345 PD-1 Protein, Human (HEK293, His-Fc)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1 Protein, Human (HEK293, His-Fc) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P705403 PD-1 Protein, Mouse (Biotinylated, HEK293, His-Avi)
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived PD-1 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P70547 PD-1 Protein, Cynomolgus (HEK293, Fc)
PD-1 is a cell surface receptor on T and B cells that binds to PD-L1 and PD-L2. PD-1 is an immune checkpoint that protects autoimmunity by promoting apoptosis of antigen-specific T cells in lymph nodes (programmed cell death) and reducing apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells). The expression of PD-L1 on tumor cells inhibits anti-tumor activity through the binding of PD-1 to effector T cells. PD-1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P700808 PD-1 Protein, Mouse (Biotinylated, HEK293, Fc)
PD-1 (programmed cell death 1) protein negatively regulates immune responses and affects processes such as apoptosis and tolerance induction. It is a transmembrane protein found on the outside of the plasma membrane and expressed in the retina. PD-1 Protein, Mouse (Biotinylated, HEK293, Fc) is the recombinant mouse-derived PD-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P705071 PD-1 Protein, Mouse (Biotinylated, HEK293, Fc-Avi)

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P705418 PD-1 Protein, Human (Biotinylated, HEK293, Fc-Avi-His)
PD-1 protein is an inhibitory receptor on T cells that maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It blocks T cell activation by binding to CD3-TCR and recruiting PTPN11/SHP-2 to dephosphorylate key signaling molecules. PD-1, Human (Biotinylated, HEK293, Fc-Avi-His) is the recombinant human-derived PD-1 protein, expressed by HEK293, with N-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules T Cell CD Proteins Macrophage CD Proteins PD-1

/
HY-P81839A PD-L2 Antibody (YA3391)
PD-L2 Antibody (YA3391) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L2.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84582 PD-1 Antibody (YA4279)
PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81603 PD-L2 Antibody (YA1348)
PD-L2 Antibody (YA1348) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81839 PD-L2 Antibody (YA1584)
PD-L2 Antibody (YA1584) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L2.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83254 alpha/beta Synuclein Antibody (YA2999)
alpha/beta Synuclein Antibody (YA2999) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha/beta Synuclein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P85925 PD-1 Antibody (YA5617)
PD-1 Antibody (YA5617) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87354 RIM2 Antibody (YA7037)
RIM2 Antibody (YA7037) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RIM2.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P84581 PD-1 Antibody (YA4278)
PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84581A PD-1 Antibody (YA4278)(PBS only)
PD-1 Antibody (YA4278) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84582A PD-1 Antibody (YA4279)(PBS only)
PD-1 Antibody (YA4279) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K0309 Mouse CD8+ T Cells Negative Selection Kit

MCE Mouse CD8+ T Cells Negative Selection Kit is designed for the isolation of CD8+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

Cell Biology Cell Isolation

/
HY-K2004 Trypan Blue Staining Solution (0.4%)

MCE Trypan Blue Staining Solution (0.4%) is suitable for viability assessment of most adherent and suspension cell lines. It is commonly used for cell culture quality control, evaluation of cellular responses following drug treatment, and viability measurements after cell thawing and recovery.

Cell Biology Cell Analysis Cell Proliferation and Cytotoxicity

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/

Keywords

non-small cell lung cancer | NSCLC | cancer neuroscience | immunotherapy | immune checkpoint inhibitors | adrenergic signaling | beta blockers | PD-1 | CD8 T cells | treatment response